Last reviewed · How we verify
NCT06374914
Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients
trial testing Intravesical Solution in Bladder Cancer in 120 participants. Not yet recruiting.
9 April 2026
Quick facts
| Lead sponsor | Dokuz Eylul University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 9 April 2024 |
| Primary completion | 9 April 2026 |
| Estimated completion | 9 April 2026 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Intravesical Solution — full drug profile →
Conditions studied
- Bladder Cancer — all drugs for Bladder Cancer →
- BCG — all drugs for BCG →
- Gemcitabine — all drugs for Gemcitabine →
- Docetaxel — all drugs for Docetaxel →
Sponsor
Dokuz Eylul University
Who can join
Adults 18 to 85, any sex, with Bladder Cancer or BCG. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Studies in the literature are limited both throughout Turkey and in general. For this reason, as a result of the study that we will create, it will provide us with information for bladder protective treatments in patients who do not respond to BCG therapy in bladder cancer patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies.
Ma Y, Sun Y, Guo H, Yang R. · · 2024 · cited 9× · PMID 39606239 · DOI 10.3389/fimmu.2024.1418131
Verify or expand the search:
- PubMed search for NCT06374914
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intravesical Solution
Trials testing the same drug.
- NCT05810623 — Single-Dose Intravesical Chemotherapy After Diagnostic URS · Phase 3 · not yet recruiting
- NCT05084586 — Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation · NA · unknown
Other recruiting trials for Bladder Cancer
Currently open trials in the same condition.
- NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
- NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
- NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
Other Dokuz Eylul University trials
Trials by the same sponsor.
- NCT07464626 — Virtual vs Physical Art Therapy for Anxiety, Psychological Well-being, and Sleep Quality in Colorectal Cancer Patients · NA · recruiting
- NCT07299058 — The Effect of a Guessing Game on Fear, Pain, and Emotional State During Blood Collection in Children Aged 6-12 · NA · not yet recruiting
- NCT07205965 — The Effect of Acceptance and Commitment Approach-Based Psychoeducation in Cancer Survivors · NA · active not recruiting
- NCT07141953 — Yoga in Women With Surgical Menopause After Gynecological Cancer · NA · not yet recruiting
- NCT07152665 — The Effect of Video-Based Educational Content for Parents and Children on Anxiety, Fear, and Pain During Blood Draw in C · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06374914 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dokuz Eylul University
- Last refreshed: 19 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06374914.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing